NVP-LAQ824 inhibits tumor growth in a BNX myeloma model. Immunodeficient BNX mice were inoculated subcutaneously in the flank with 3 × 10⁷ RPMI 8226 MM cells in 100 μL RPMI 1640 medium, together with 100 μL Matrigel. Daily intraperitoneal administration of NVP-LAQ824 (25 mg/kg) starting after the development of measurable tumor significantly reduced MM tumor growth (A-B) (P = .007), and increased survival (C) (P = .004), compared with the control group treated with vehicle (normal saline) only. (A) Treated (--); control (—). (B) Treated (□); control (▪). Error bars in panel A represent ± 1 SD of 9 mice in the treated group and 13 mice in the control group.